Post-marketing safety of bimekizumab in psoriasis patients: pharmacovigilance data from FDA adverse event reporting system

Published: 10 September 2025| Version 1 | DOI: 10.17632/frj26x6z2t.1
Contributor:
Tung Tran

Description

The set of supplementary materials support findings of the study "Post-marketing safety of bimekizumab in psoriasis patients: pharmacovigilance data from FDA adverse event reporting system" which has been accepted in the International Journal of Dermatology. The dataset includes Supplementary Methods and 2 Supplementary Tables.

Files

Institutions

  • Mayo Clinic Rochester
  • Hanoi Medical University

Categories

Clinical Research

Licence